JUN 22, 2020 9:03 AM PDT

Black patients are underrepresented in clinical trials

Amidst the swell of racial injustice that the country is bringing to light, new research reports that Black patients are better represented in taxpayer-funded clinical trials testing new cancer treatments compared to trials run by pharmaceutical companies. This finding, published in April this year in JNCI Cancer Spectrum, will be presented this week at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II. 

To put these findings into context, it is essential to know that Black patients are not fully represented in cancer clinical trials, regardless of who is the sponsor. These cancer disparities are a crucial part of the greater picture of racial injustice that we need to expose. 

The study was led by Joseph Unger, PhD, who specializes in cancer disparities research, particularly in regards to the impacts of insurance status, race and ethnicity, and income on health outcomes. Unger is a biostatistician at SWOG Cancer Research Network, a member of the National Cancer Institute's National Clinical Trials Network (NCTN), which has run thousands of trials over the last 60 years. 

In this study, Unger analyzed black enrollment in NCI-sponsored trials and industry-sponsored trials. "It's a critical question," Unger said. "Trials are an important way - sometimes the only way - for cancer patients to receive potentially breakthrough drugs. Everyone can get cancer, so everyone should have the same access to investigational cancer treatments. In addition, it's very important from a scientific standpoint to evaluate new treatments in patients who reflect the demographics of the general cancer population."

"This study confirmed that black cancer patients are severely underrepresented in pharmaceutical company-sponsored trials, with fewer than one in four of the expected number enrolled," Unger said. "Black representation in industry trials was also far below that of NCTN trials, with only one black patient enrolled for every three enrolled in NCTN trials."

The research team took data from 358 trials, 85 of which were from industry and 273 of which were SWOG trials. From the years of 2003 to 2018, these trials enrolled 93,825 patients being treated for 15 different cancer types. They found that the rate of black enrollment in industry trials was 3%, compared to 9% in SWOG trials and 12% in the corresponding U.S. cancer population. 

Black patients are underrepresented in clinical trials. Photo: Pixabay

Unger hopes that presenting the findings from this study will improve the representation of Black patients throughout all clinical trials. "NCI sponsored trials have a broader mandate," he said. "They reach beyond just the major cancer centers to serve patients in a more diverse community-based clinical setting. This could serve as a model for pharma trials aiming to increase the representativeness of all patients."

Sources: JNCI Cancer Spectrum, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
JUN 18, 2020
Cancer
The Importance of Timing in the Standard Treatment of Glioma
JUN 18, 2020
The Importance of Timing in the Standard Treatment of Glioma
Glioblastomas, the most common form of brain cancer, are very aggressive and have a standard three-stage treatment. The ...
JUN 17, 2020
Cancer
New test for high-grade serous ovarian cancer
JUN 17, 2020
New test for high-grade serous ovarian cancer
Research published in Clinical Cancer Research describes a new test that is more effective at diagnosing ovarian cancer. ...
JUL 08, 2020
Drug Discovery & Development
Common Blood Pressure Drugs May Prevent Colon Cancer
JUL 08, 2020
Common Blood Pressure Drugs May Prevent Colon Cancer
Colon cancer is the third most common cancer and the second leading cause of death by cancer around the world. Now, rese ...
JUL 15, 2020
Cancer
Traditional Medicine Reveals a New Anti-Cancer Drug
JUL 15, 2020
Traditional Medicine Reveals a New Anti-Cancer Drug
The art of traditional eastern medicine dates back thousands of years. It uses many unproven remedies, and many consider ...
JUL 17, 2020
Cancer
Tackling the Problem of Toxicity in Breast Cancer Therapy
JUL 17, 2020
Tackling the Problem of Toxicity in Breast Cancer Therapy
Chemotherapy has been one of the primary methods of cancer treatment for decades. Usually, a doctor applies a chemothera ...
JUL 28, 2020
Clinical & Molecular DX
Cancer Diagnostics Go Skin Deep
JUL 28, 2020
Cancer Diagnostics Go Skin Deep
The average adult human has between 16 and 22 square feet of skin. This multifaceted organ serves a multitude of functio ...
Loading Comments...